= Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Execution Version GLOBAL ACCESS COMMITMENTS AGREEMENT GRANT AGREEMENT...Global Access Commitments Agreement • May 5th, 2020 • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, this “GACA”), is entered into as of date of last signature below (“Effective Date”) by and between the Bill and Melinda Gates Foundation, a Washington Charitable Trust (the “Foundation”) and Novavax, Inc., a Delaware corporation based in Maryland (“Novavax” or the “Company”) in connection with the Foundation making a charitable grant of up to eighty nine million, eighty three thousand three hundred twelve U.S. dollars ($89,083,312.00) to Company (the “Grant”) and is subject to the terms and conditions of the Grant Agreement and related documents, including but not limited to this GACA. Each of the parties named above may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meaning as in the Grant Agreement. In consideration of the Foundation making the grant on the terms and conditions in the Grant Agreement and h
Global Access Commitments AgreementGlobal Access Commitments Agreement • July 31st, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of February 13, 2015 (“Effective Date”), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), and CureVac GmbH, a German limited company, together with its Affiliates (“CureVac” or the “Company”), in connection with the Foundation making a program-related investment in the Company by acquiring Series B Shares of the Company issued from the Company as part of one or more capital increases (the “Shares”) (the acquisition of Shares is referred to herein as the “Foundation Investment”). The Foundation Investment is subject to the terms and conditions of the investment documents executed in connection with the closing (“Closing”), including, without limitation, this Agreement, and the Investment and Shareholders’ Agreement (the “Shareholders’ Agreement”) among the Com
FIRST AMENDMENT TO AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS AGREEMENTGlobal Access Commitments Agreement • February 3rd, 2021 • Immunocore Holdings PLC • Biological products, (no disgnostic substances) • London
This FIRST AMENDMENT TO AMENDED AND RESTATED GLOBAL ACCESS COMMITMENTS AGREEMENT (“Agreement”) is dated as of the 3rd day of February, 2021, by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), Immunocore public Limited, a private limited company incorporated in England and Wales with company number 06456207 (the “Company”), and Immunocore Holdings plc, a private limited company incorporated under the laws of England and Wales (“Holdings”).
Amended & Restated Global Access Commitments AgreementGlobal Access Commitments Agreement • January 15th, 2021 • Immunocore LTD • Biological products, (no disgnostic substances) • London
This Amended & Restated Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of 2 March 2020 (“Effective Date”), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), and Immunocore Limited, a company incorporated in England and Wales with registered number 06456207 (the “Company”). This Agreement amends and restates in its entirety the Global Access Commitments Agreement entered into as of September 13, 2017 (the “Prior Agreement”), which was entered into by and between the Foundation and the Company in connection with the Foundation’s investment (the “Notes Investment”) in promissory notes issued by the Company (the “Notes”) of up to forty million dollars ($US40,000,000) and, upon conversion of the Notes (the “Notes Conversion”), equity securities of the Company. In addition to the Notes Investment, additional payments
Global Access Commitments AgreementGlobal Access Commitments Agreement • September 27th, 2021 • Exscientia LTD • Biological products, (no disgnostic substances) • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”) is entered into as of September 1, 2021 (“Effective Date”), by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), Exscientia Limited (registered number 13483814), a private limited company incorporated in England and Wales (the “Company”) and Exscientia AI Limited, (registered number SC428761), a private limited company incorporated under the laws of Scotland that is a wholly-owned subsidiary of the Company (“Exscientia”), in connection with the investment by the Foundation of Thirty-Five Million dollars (US$35,000,000) (the “Foundation Investment”) in American Depositary Shares of the Company. The Foundation is making the Foundation Investment to induce the Company and Exscientia to perform the Global Access Commitments set forth herein, and the Company and Exscientia acknowledge and
GLOBAL ACCESS COMMITMENTS AGREEMENTGlobal Access Commitments Agreement • August 29th, 2022 • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, this “GACA”), is entered into as of date of last signature below (“Effective Date”) by and between the Bill and Melinda Gates Foundation, a Washington Charitable Trust (the “Foundation”) and Novavax, Inc., a Delaware corporation based in Maryland (“Novavax” or the “Company”) in connection with the Foundation making a charitable grant of up to eighty nine million, eighty three thousand three hundred twelve U.S. dollars ($89,083,312.00) to Company (the “Grant”) and is subject to the terms and conditions of the Grant Agreement and related documents, including but not limited to this GACA. Each of the parties named above may be referred to herein as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meaning as in the Grant Agreement. In consideration of the Foundation making the grant on the terms and conditions in the Grant Agreement and h
FIRST AMENDMENT AND JOINDER TO GLOBAL ACCESS COMMITMENTS AGREEMENTGlobal Access Commitments Agreement • August 7th, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This FIRST AMENDMENT AND JOINDER TO GLOBAL ACCESS COMMITMENTS AGREEMENT ("Agreement") is dated as of the 15th day of July, 2020, by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the "Foundation"), CureVac AG, a stock corporation incorporated in Germany ("CureVac AG"), and CureVac B.V., a Dutch private company with limited liability ("CureVac BV", or after its change of legal form as described below, "CureVac NV").
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. SECOND AMENDMENT TO GLOBAL ACCESS COMMITTMENTS...Global Access Commitments Agreement • August 7th, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO GLOBAL ACCESS COMMITMENTS AGREEMENT ("Agreement") is effective as of the 15th day of July, 2020, by and among the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the "Foundation") and CureVac AG, a German stock corporation (the "Company").
